Oncology Research

abinScience provides a comprehensive oncology reagent portfolio spanning immune checkpoint proteins (PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3), tumor-associated antigens, oncogenic driver pathway antibodies, ADC targets, and biosimilar-grade reference proteins for cancer research across 20+ tumor types. RUO

Explore by Cancer Type

Lung Cancer

EGFR, ALK, KRAS, PD-L1, VEGF — NSCLC driver mutations and checkpoint reagents.

Breast Cancer

HER2, ER, PR, Ki-67, TROP2, Nectin-4 — subtyping and ADC targets.

Colorectal Cancer

KRAS, BRAF, MSI/MMR, CEA, EGFR — molecular profiling and monitoring.

Melanoma

BRAF, PD-1, CTLA-4, LAG-3, gp100, S100 — MAPK pathway and immunotherapy.

Gastric / GEJ Cancer

HER2, Claudin 18.2, FGFR2b, PD-L1 — targeted therapy biomarkers.

Lymphoma

CD20, CD19, CD30, CD47, BCL2 — B-cell targets and CAR-T antigens.

Reagents by Therapeutic Modality

Immune Checkpoint InhibitorsPD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3, IDO1, CD47 — 800+ antibodies, recombinant proteins, and biosimilar references for IO research.

ADC & Bispecific TargetsHER2, TROP2, Nectin-4, Claudin 18.2, Mesothelin, CD33, EGFR, B7-H3 — target proteins and antibodies for next-gen biologics development.

CAR-T Cell TherapyCD19, CD20, CD22, BCMA, CD33, CD123, GPC3, Mesothelin — recombinant proteins for CAR construct binding and antigen density profiling.

Oncogenic Signaling PathwaysEGFR, HER2, KRAS, BRAF, ALK, FGFR, MET, PI3K/AKT/mTOR, VEGF/VEGFR — RTK and downstream effector antibodies for drug mechanism studies.

Tumor MicroenvironmentPD-L1, CD8, FOXP3, CD68, CD163, IDO1 — immune cell phenotyping antibodies for tumor-immune interaction studies.

Why Researchers Choose abinScience for Oncology

Full target chain: Recombinant protein → antibody → ELISA kit for the same target, from one manufacturer. Streamline assay development and reduce vendor complexity.
Biosimilar-grade references: Research-grade biosimilars of approved checkpoint and targeted therapy antibodies for analytical similarity, potency, and PK studies.
Original manufacturer pricing: Direct-from-manufacturer with no distributor markup. Bulk discounts and custom conjugation available.
Custom antibody upgrade path: Can't find your target? Our parent company AtaGenix offers end-to-end custom antibody development from antigen design through hybridoma production.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

How many oncology-related targets do you cover?

We offer products for 9,000+ unique targets across 35,000+ SKUs, with deep coverage of immuno-oncology checkpoints, RTK signaling, tumor-associated antigens, and ADC targets spanning 20+ cancer types.

Do you offer biosimilar reference proteins for approved drugs?

Yes. We carry research-grade biosimilars for checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, ipilimumab), anti-HER2 (trastuzumab, pertuzumab), anti-EGFR (cetuximab), anti-CD20 (rituximab), and more.

How do I find the right reagent for my application?

Product pages list validated applications (WB, IHC, IF, ELISA, FC). Use our target search to filter by application, species, and cancer type. Our technical team is available for personalized recommendations.

Do you support multiplex IHC panels?

We provide individual antibodies that can be assembled into custom multiplex panels. Contact our technical team for guidance on sequential or simultaneous multiplex IHC workflow design.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.